Switch theme
Sign up to access all valuation multiples
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
2004
270
LTM Revenue $7.6M
LTM EBITDA -$183M
$554M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
KalVista Pharmaceuticals has a last 12-month revenue (LTM) of $7.6M and a last 12-month EBITDA of -$183M.
In the most recent fiscal year, KalVista Pharmaceuticals achieved revenue of n/a and an EBITDA of -$173M.
KalVista Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See KalVista Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $6.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$183M | XXX | -$173M | XXX | XXX | XXX |
| EBITDA Margin | -2408% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$186M | XXX | -$183M | XXX | XXX | XXX |
| EBIT Margin | -2446% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$181M | XXX | -$183M | XXX | XXX | XXX |
| Net Margin | -2385% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, KalVista Pharmaceuticals's stock price is $15.
KalVista Pharmaceuticals has current market cap of $769M, and EV of $554M.
See KalVista Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $554M | $769M | XXX | XXX | XXX | XXX | $-3.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, KalVista Pharmaceuticals has market cap of $769M and EV of $554M.
KalVista Pharmaceuticals's trades at n/a EV/Revenue multiple, and -3.5x EV/EBITDA.
Equity research analysts estimate KalVista Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
KalVista Pharmaceuticals has a P/E ratio of -4.2x.
See valuation multiples for KalVista Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $769M | XXX | $769M | XXX | XXX | XXX |
| EV (current) | $554M | XXX | $554M | XXX | XXX | XXX |
| EV/Revenue | 72.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | -3.5x | XXX | XXX | XXX |
| EV/EBIT | -3.0x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 82.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.2x | XXX | -4.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKalVista Pharmaceuticals's last 12 month revenue growth is 577%
KalVista Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.
KalVista Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
KalVista Pharmaceuticals's rule of X is -964% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for KalVista Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 577% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2408% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -3% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -964% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
KalVista Pharmaceuticals acquired XXX companies to date.
Last acquisition by KalVista Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . KalVista Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was KalVista Pharmaceuticals founded? | KalVista Pharmaceuticals was founded in 2004. |
| Where is KalVista Pharmaceuticals headquartered? | KalVista Pharmaceuticals is headquartered in United States of America. |
| How many employees does KalVista Pharmaceuticals have? | As of today, KalVista Pharmaceuticals has 270 employees. |
| Who is the CEO of KalVista Pharmaceuticals? | KalVista Pharmaceuticals's CEO is Mr. Benjamin L. Palleiko. |
| Is KalVista Pharmaceuticals publicy listed? | Yes, KalVista Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of KalVista Pharmaceuticals? | KalVista Pharmaceuticals trades under KALV ticker. |
| When did KalVista Pharmaceuticals go public? | KalVista Pharmaceuticals went public in 2015. |
| Who are competitors of KalVista Pharmaceuticals? | Similar companies to KalVista Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of KalVista Pharmaceuticals? | KalVista Pharmaceuticals's current market cap is $769M |
| What is the current revenue of KalVista Pharmaceuticals? | KalVista Pharmaceuticals's last 12 months revenue is $7.6M. |
| What is the current revenue growth of KalVista Pharmaceuticals? | KalVista Pharmaceuticals revenue growth (NTM/LTM) is 577%. |
| What is the current EV/Revenue multiple of KalVista Pharmaceuticals? | Current revenue multiple of KalVista Pharmaceuticals is 72.9x. |
| Is KalVista Pharmaceuticals profitable? | Yes, KalVista Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of KalVista Pharmaceuticals? | KalVista Pharmaceuticals's last 12 months EBITDA is -$183M. |
| What is KalVista Pharmaceuticals's EBITDA margin? | KalVista Pharmaceuticals's last 12 months EBITDA margin is -2408%. |
| What is the current EV/EBITDA multiple of KalVista Pharmaceuticals? | Current EBITDA multiple of KalVista Pharmaceuticals is -3.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
